We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00130286
First Posted: August 15, 2005
Last Update Posted: February 13, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Marshall Jay Glesby, MD, PhD, Weill Medical College of Cornell University
Results First Submitted: December 16, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV-Associated Lipodystrophy Syndrome
Insulin Resistance
HIV Infections
Metabolic Syndrome X
Body Weight Changes
Interventions: Drug: Rosiglitazone
Drug: Recombinant human growth hormone + rosiglitazone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
rhGH + Rosi

Recombinant human growth hormone + rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

rhGH Placebo + Rosi

Placebo for recombinant human growth hormone + rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

rhGH + Rosi Placebo

Recombinant human growth hormone + placebo for rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Double Placebo

Placebo for recombinant human growth hormone + placebo for rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)


Participant Flow:   Overall Study
    rhGH + Rosi   rhGH Placebo + Rosi   rhGH + Rosi Placebo   Double Placebo
STARTED   22   19   17   19 
COMPLETED   22   16   13   17 
NOT COMPLETED   0   3   4   2 
Withdrawal by Subject                0                1                2                2 
Adverse Event                0                0                2                0 
Missing lab specimens                0                2                0                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
rhGH + Rosi

Recombinant human growth hormone + rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

rhGH Placebo + Rosi

Placebo for recombinant human growth hormone + rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

rhGH + Rosi Placebo

Recombinant human growth hormone + placebo for rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Double Placebo

Placebo for recombinant human growth hormone + placebo for rosiglitazone

Rosiglitazone: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Recombinant human growth hormone + rosiglitazone: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Total Total of all reporting groups

Baseline Measures
   rhGH + Rosi   rhGH Placebo + Rosi   rhGH + Rosi Placebo   Double Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 22   19   17   19   77 
Age 
[Units: Years]
Mean (Standard Deviation)
 46.8  (9.4)   49.3  (6.1)   48.6  (4.9)   46.6  (6.7)   47.9  (7.1) 
Gender 
[Units: Participants]
         
Female   4   4   3   6   17 
Male   18   15   14   13   60 
Race (NIH/OMB) 
[Units: Participants]
         
American Indian or Alaska Native   0   0   0   0   0 
Asian   0   0   0   0   0 
Native Hawaiian or Other Pacific Islander   0   0   0   0   0 
Black or African American   6   6   6   6   24 
White   15   11   11   12   49 
More than one race   1   2   0   1   4 
Unknown or Not Reported   0   0   0   0   0 
Ethnicity (NIH/OMB) 
[Units: Participants]
         
Hispanic or Latino   9   9   3   9   30 
Not Hispanic or Latino   13   10   14   10   47 
Unknown or Not Reported   0   0   0   0   0 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Insulin Sensitivity   [ Time Frame: 12 weeks ]

2.  Secondary:   Change in Visceral Adipose Tissue Volume   [ Time Frame: 12 weeks ]

3.  Secondary:   Change in Subcutaneous Adipose Tissue Volume   [ Time Frame: 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Marshall J. Glesby
Organization: Weill Cornell Medical College
phone: 212-746-4177
e-mail: mag2005@med.cornell.edu


Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Marshall Jay Glesby, MD, PhD, Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT00130286     History of Changes
Other Study ID Numbers: 65515
R01DK065515 ( U.S. NIH Grant/Contract )
First Submitted: August 12, 2005
First Posted: August 15, 2005
Results First Submitted: December 16, 2013
Results First Posted: February 13, 2014
Last Update Posted: February 13, 2014